Synaffix obtains exclusive rights to the CliCr technology, to combine with its proprietary ADC platform technology CliCr further expands the repertoire of payloads suitable for conjugation by
/PRNewswire/ Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of.
New Data Opens Potential for Patient Stratification for CriPec® Nanomedicines in Cancer and Other Indications via Non-Invasive ImagingMaastricht, The Netherlands, 4 May 2022 – Cristal Therapeutics, a Dutch pharmaceutical company developing tailored nanomedicines for the treatment of cancer and other d.